ArticleEuropean journal of clinical pharmacology2023

Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).

Jialing Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.